The 2026 Acute Pulmonary Embolism Guidelines were recently released. They recommend low-molecular-weight heparin (LMWH) over heparin for hospitalized patients with acute PE who require initial parenteral therapy unless they are in Category E2 Acute PE Cardiopulmonary Failure (level 1B-R).

Top benefits include:

• Reduce recurrent VTE
• Reduce bleeding
• More predictable response

References

2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines | Circulation